Paragon Associates & Paragon Associates II Joint Venture’s DiaMedica Therapeutics DMAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.54M | Buy |
650,000
+50,000
| +8% | +$195K | 4.03% | 11 |
|
|
2025
Q1 | $2.27M | Buy |
600,000
+85,216
| +17% | +$323K | 5.33% | 7 |
|
|
2024
Q4 | $2.8M | Buy |
514,784
+32,170
| +7% | +$175K | 6.46% | 6 |
|
|
2024
Q3 | $2.02M | Hold |
482,614
| – | – | 3.63% | 10 |
|
|
2024
Q2 | $1.42M | Sell |
482,614
-17,386
| -3% | -$51.3K | 3.48% | 10 |
|
|
2024
Q1 | $1.39M | Hold |
500,000
| – | – | 2.47% | 15 |
|
|
2023
Q4 | $1.42M | Buy |
500,000
+30,000
| +6% | +$85.2K | 3.26% | 11 |
|
|
2023
Q3 | $1.21M | Buy |
470,000
+145,000
| +45% | +$374K | 3.97% | 7 |
|
|
2023
Q2 | $1.4M | Buy |
+325,000
| New | +$1.4M | 2.87% | 9 |
|